Table 1

Resistance of cMOAT transfected LLC/cMOAT-1 cells to anticancer agents and heavy metals

Agent	IC₅₀		Relative^1-aResistance
Agent	LLC/CMV	LLC/cMOAT-1	Relative^1-aResistance
	μM
VCR	0.029 ± 0.002	0.234 ± 0.018	8.02^1-b
SN-38	0.065 ± 0.007	0.408 ± 0.041	6.28^1-b
Cisplatin	2.576 ± 0.354	7.820 ± 0.844	3.04^1-b
ADM	1.211 ± 0.103	2.459 ± 0.214	2.03^1-b
CPT-11	28.230 ± 3.313	43.832 ± 5.152	1.55^1-b
Etoposide	6.230 ± 0.815	7.020 ± 0.865	1.13
MX	2.553 ± 0.214	2.770 ± 0.188	1.09
Taxol	3.713 ± 0.285	4.541 ± 0.324	1.22
Sb III^1-c	9.198 ± 0.844	8.665 ± 0.924	0.94
As III^1-d	9.102 ± 0.835	7.692 ± 0.895	0.85

Cells (6 × 10³ LLC/CMV and LLC/cMOAT-1) were inoculated into 96-well plates. After overnight incubation, various agents or compounds were added and the incubation was continued for 4 days. Thereafter, 50 μl of MTT was added to each well and the plates were incubated for 4 h. After aspiration of the culture medium, the resulting formazan was dissolved with dimethylsulfoxide. Plates were placed on a shaker for 5 min and read immediately at 570 nm with a microplate reader, MRP-A4i (Tosoh, Tokyo). Data represent means of triplicate determinations (± S.E.) from at least three separate experiments.

↵1-a Relative resistance was calculated as the ratio of the IC₅₀ of LLC/cMOAT-1 to the IC₅₀ of LLC/CMV cells.
↵1-b Values obtained with a transfected LLC/cMOAT-1 and cell line are significantly different from those obtained with its corresponding sensitive control cell line, LLC/CMV cells (P < .05).
↵1-c Antimony potassium tartrate.
↵1-d Sodium arsenite.